REBBLS x BII: Enablers in Biotech
Being recognized as an enabler of biotech and an emerging contributor to the field of drug discovery and development, Synobody is thrilled to be chosen as a one of five speakers at this event.
This recognition further solidifies Synobody's position as a driving force within the Danish life science community. We are proud to contribute to the advancement of cutting-edge technologies and therapeutic solutions that have the potential to transform patient care.
April 9th, 2023
Next Unicorn Award
Synobody won the prize "Next Unicorn Award" in the Beyond Beta Accelerator program final.
Synobody was carefully selected among +100 applicants and successfully completed Beyond Beta’s accelerator as one of the top-10 startups amongst 50 companies, who made it through the entire 5-months program.
February 9th, 2023
Innovation Fund Denmark grant
We are thrilled to announce that Synobody is accepted into the Innofounder program granted by the Innovation Fund Denmark (Innovationsfonden).
The program runs for a year and includes funding and expert help, which will support Synobody's mission and vision of making nanobodies more accessible worldwide.
February 1st, 2023
Synobody joins Beyond Beta Accelerator
We are happy to announce that synobody has been accepted into the Beyond Beta Accelerator program starting the 6th of October.
The program is for startups with growth ambitions and it strives to support founders in setting their businesses up for private investment and rapid scaling.
October 1st, 2022
Synobody receives micro grant
In May 2021 Synobody was on the list of companies receiving the Micro Grant from The Danish Foundation for Entrepreneurship. The grant was for the sum of 50,000 DKK.
May 1st, 2021
